Clinical development of Modified Vaccinia virus Ankara vaccines.

Clinical development of Modified Vaccinia virus Ankara vaccines.

अन्य संस्करण दिखाएं (1)

The smallpox vaccine Vaccinia was successfully used to eradicate smallpox, but although very effective, it was a very reactogenic vaccine and responsible for the deaths of one or two people per million vaccinated. Modified Vaccinia virus Ankara (MVA) is a replication-deficient and attenuated derivat...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखक:	Gilbert, S
स्वरूप:	Journal article
भाषा:	English
प्रकाशित:	2013

समान संसाधन

Clinical development of Modified Vaccinia virus Ankara vaccines
द्वारा: Gilbert, S
प्रकाशित: (2013)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
द्वारा: Olga Vladimirovna Orlova, और अन्य
प्रकाशित: (2022-09-01)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
द्वारा: Gilbert, S, और अन्य
प्रकाशित: (1999)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
द्वारा: Moorthy, V, और अन्य
प्रकाशित: (2003)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
द्वारा: Kaïdre Bendjama, और अन्य
प्रकाशित: (2017-09-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
द्वारा: Volker Sandig, और अन्य
प्रकाशित: (2013-11-01)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
द्वारा: Juan García-Arriaza, और अन्य
प्रकाशित: (2021-08-01)

Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans
द्वारा: Alina Tscherne, और अन्य
प्रकाशित: (2024-11-01)

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers
द्वारा: López-Camacho, C, और अन्य
प्रकाशित: (2019)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
द्वारा: Alharbi, N
प्रकाशित: (2014)

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
द्वारा: César López-Camacho, और अन्य
प्रकाशित: (2019-11-01)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
द्वारा: Caroline Staib, और अन्य
प्रकाशित: (2003-04-01)

Ebola virus – prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine
द्वारा: Harriet L. Robinson, और अन्य
प्रकाशित: (2018-09-01)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
द्वारा: McConkey, S, और अन्य
प्रकाशित: (2003)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
द्वारा: Rosario, M, और अन्य
प्रकाशित: (2010)

Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
द्वारा: Flavia Chiuppesi, और अन्य
प्रकाशित: (2024-02-01)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
द्वारा: Mingwang Shen, और अन्य
प्रकाशित: (2024-10-01)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
द्वारा: Alharbi, N, और अन्य
प्रकाशित: (2015)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
द्वारा: C. Staib, और अन्य
प्रकाशित: (2000-06-01)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
द्वारा: Malachy I. Okeke, और अन्य
प्रकाशित: (2017-10-01)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.
द्वारा: Naif Khalaf Alharbi, और अन्य
प्रकाशित: (2015-01-01)

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
द्वारा: Moorthy, V, और अन्य
प्रकाशित: (2003)

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers
द्वारा: Moorthy, V, और अन्य
प्रकाशित: (2003)

Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA)
द्वारा: Schmidt, C, और अन्य
प्रकाशित: (2008)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
द्वारा: Behboudi, S, और अन्य
प्रकाशित: (2004)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
द्वारा: Schneider, J, और अन्य
प्रकाशित: (1998)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
द्वारा: Dorrell, L, और अन्य
प्रकाशित: (2000)

Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
द्वारा: Nereida Jiménez de Oya, और अन्य
प्रकाशित: (2022-03-01)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
द्वारा: Hanke, T, और अन्य
प्रकाशित: (1998)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
द्वारा: Cottingham, M, और अन्य
प्रकाशित: (2008)

Genome Sequencing of a Camelpox Vaccine Reveals Close Similarity to Modified <i>Vaccinia virus</i> Ankara (MVA)
द्वारा: Maurilia Marcacci, और अन्य
प्रकाशित: (2020-07-01)

Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
द्वारा: Ning Yang, और अन्य
प्रकाशित: (2022-10-01)

Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored ebola vaccines at 1 year
द्वारा: Winslow, R, और अन्य
प्रकाशित: (2017)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
द्वारा: Matthew G Cottingham, और अन्य
प्रकाशित: (2008-02-01)

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
द्वारा: David A Garber, और अन्य
प्रकाशित: (2009-01-01)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
द्वारा: Goepfert P, और अन्य
प्रकाशित: (2012-09-01)

Therapeutic vaccination against hepatitis B virus using heterolgous prime boost strategy with DNA and modified vaccinia virus ankara vectors
द्वारा: McConkey, S, और अन्य
प्रकाशित: (2003)

Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model.
द्वारा: Miriam Nörder, और अन्य
प्रकाशित: (2010-01-01)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
द्वारा: Mcshane, H, और अन्य
प्रकाशित: (2001)

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
द्वारा: Hanke, T, और अन्य
प्रकाशित: (2007)